MetaCap

Cabaletta Bio (CABA) vs Century Therapeutics (IPSC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Century Therapeutics (IPSC) has outperformed Cabaletta Bio (CABA) over the past year, gaining 137.8% versus a loss of 55.0%. Over five years, CABA leads with a -91.9% price change compared with -93.2% for IPSC. Century Therapeutics is the larger company by market cap ($211.6 million vs $201.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CABA-55.00%IPSC+137.76%
+528%+223%-83%
Nov 21, 20251 yearNov 20, 2026
CABA-92.19%IPSC-94.35%
+119%+5%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CABA versus IPSC key metrics
MetricCABAIPSC
Share price$0.9361$1.17
Market cap$201.94M$211.56M
1-day change-7.32%-11.74%
YTD return-57.26%+17.09%
1-year return-55.00%+137.76%
5-year return-91.93%-93.23%
EPS (TTM)$-1.33$-0.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$109.16M
Revenue growth (YoY)—+1556.76%
Net income (latest FY)$-167.86M$-9.58M
Operating margin—-15.82%
Net margin—-8.78%
52-week high$4.23$3.04
52-week low$0.93$0.48
Distance from 52-week high-77.87%-61.68%
Analyst consensusstrong_buybuy
Avg. price target upside+1155.21%+307.73%
Average volume5.15M759.69K
Shares outstanding215.72M181.60M
Employees15478
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IPSC has outperformed CABA by 192.8 percentage points over the past year.

About Cabaletta Bio

CABA stock →

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees

About Century Therapeutics

IPSC stock →

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees

CABA vs IPSC FAQ

Which is bigger, Cabaletta Bio or Century Therapeutics?

Century Therapeutics (IPSC) is larger, with a market capitalization of $211.56M compared with $201.94M for Cabaletta Bio (CABA).

Which stock has performed better over the past year, CABA or IPSC?

IPSC returned +137.76% over the past 12 months, compared with -55.00% for CABA (price return, excluding dividends). Past performance does not predict future results.

Are Cabaletta Bio and Century Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons